Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population

BMC Gastroenterology

Volumn 12, Issue , 2012, Pages

  Sumida, Yoshio ^a   Yoneda, Masato ^b   Hyogo, Hideyuki ^c   Itoh, Yoshito ^d   Ono, Masafumi ^e   Fujii, Hideki ^f   Eguchi, Yuichiro ^g   Suzuki, Yasuaki ^h   Aoki, Noriaki ⁱ   Kanemasa, Kazuyuki ^a   Fujita, Koji ^b   Chayama, Kazuaki ^c   Saibara, Toshiji ^e   Kawada, Norifumi ^f   Fujimoto, Kazuma ^g   Kohgo, Yutaka ^h   Yoshikawa, Toshikazu ^d   Okanoue, Takeshi ^j  

^a Nara City Hospital   (Japan)

^b YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c HIROSHIMA UNIVERSITY   (Japan)

^d KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^e KOCHI MEDICAL SCHOOL   (Japan)

^f OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^g SAGA UNIVERSITY   (Japan)

^h ASAHIKAWA MEDICAL COLLEGE   (Japan)

ⁱ UNIVERSITY OF TEXAS   (United States)

^j Saiseikai Imperial Gift Foundation Inc Saiseikai Suita Hospital   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; FEMALE; FIB4 INDEX; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; JAPANESE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NON INVASIVE MEASUREMENT; NONALCOHOLIC FATTY LIVER; PREDICTIVE VALUE; RECEIVER OPERATING CHARACTERISTIC; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; VALIDATION STUDY; AGE; AGED; BIOPSY; BLOOD; COHORT ANALYSIS; ETHNOLOGY; FATTY LIVER; HOSPITALIZATION; JAPAN; LIVER; LIVER CIRRHOSIS; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY; THROMBOCYTE COUNT;

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER;

ADULT; AGE FACTORS; AGED; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; BIOPSY; COHORT STUDIES; FATTY LIVER; FEMALE; HUMANS; JAPAN; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PLATELET COUNT; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; ROC CURVE; SEVERITY OF ILLNESS INDEX;

EID: 84855390033     PISSN: None     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/1471-230X-12-2     Document Type: Article

References (37)

1. Ludwig J, Viggiano TR, McGill DB, Ott BJ. Non-alcoholic steatohepatitis. Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980, 55:434-438.
2. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver diseases: a spectrum of clinical and pathological severity. Gastroenterology 1999, 116:1413-1419. 10.1016/S0016-5085(99)70506-8, 10348825.
3. Rafiq N, Bai C, Fang Y, Srishord M, McCullough A, Gramlich T, Younossi ZM. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol 2009, 7:234-238. 10.1016/j.cgh.2008.11.005, 19049831.
4. Ono M, Saibara T. Clinical features of nonalcoholic steatohepatitis in Japan: evidence from literature. J Gastroenterol 2006, 41:725-732. 10.1007/s00535-006-1876-0, 16988759.
5. Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology 2009, 49:306-317. 10.1002/hep.22603, 2766096, 19065650.
6. Wieckowska A, McCullough AJ, Feldstein AE. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology 2007, 46:582-589. 10.1002/hep.21768, 17661414.
7. Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, Grimaldi A, Capron F, Poynard T, . LIDO Study Group Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005, 128:1898-1906. 10.1053/j.gastro.2005.03.084, 15940625, LIDO Study Group.
8. Merriman RB, Ferrell LD, Patti MG, Weston SR, Pabst MS, Aouizerat BE, Bass NM. Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease. Hepatology 2006, 44:874-880. 10.1002/hep.21346, 17006934.
9. Ratziu V, Massard J, Charlotte F, Messous D, Imbert-Bismut F, Bonyhay L, Tahiri M, Munteanu M, Thabut D, Cadranel JF, Le Bail B, de Ledinghen V, Poynard T, . LIDO Study Group; CYTOL study group Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 2006, 6:6. 10.1186/1471-230X-6-6, 1386692, 16503961, LIDO Study Group; CYTOL study group.
10. Guha IN, Parkes J, Roderick P, Chattopadhyay D, Cross R, Harris S, Kaye P, Burt AD, Ryder SD, Aithal GP, Day CP, Rosenberg WM. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 2008, 47:455-460.
11. Huwart L, Sempoux C, Salameh N, Jamart J, Annet L, Sinkus R, Peeters F, ter Beek LC, Horsmans Y, Van Beers BE. Liver fibrosis: noninvasive assessment with MR elastography versus aspartate aminotransferase- to-platelet ratio index. Radiology 2007, 245:458-466. 10.1148/radiol.2452061673, 17940304.
12. Yoneda M, Yoneda M, Mawatari H, Fujita K, Endo H, Iida H, Nozaki Y, Yonemitsu K, Higurashi T, Takahashi H, Kobayashi N, Kirikoshi H, Abe Y, Inamori M, Kubota K, Saito S, Tamano M, Hiraishi H, Maeyama S, Yamaguchi N, Togo S, Nakajima A. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD). Dig Liver Dis 2008, 40:371-378. 10.1016/j.dld.2007.10.019, 18083083.
13. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, Enders F, Saksena S, Burt AD, Bida JP, Lindor K, Sanderson SO, Lenzi M, Adams LA, Kench J, Therneau TM, Day CP. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007, 45:846-854. 10.1002/hep.21496, 17393509.
14. Ratziu V, Giral P, Charlotte F, Bruckert E, Thibault V, Theodorou I, Khalil L, Turpin G, Opolon P, Poynard T. Liver fibrosis in overweight patients. Gastroenterology 2000, 118:1117-1123. 10.1016/S0016-5085(00)70364-7, 10833486.
15. Yoneda M, Suzuki K, Kato S, Fujita K, Nozaki Y, Hosono K, Saito S, Nakajima A. Nonalcoholic fatty liver disease: US-based acoustic radiation force impulse elastography. Radiology 2010, 256:640-647. 10.1148/radiol.10091662, 20529989.
16. Suzuki A, Angulo P, Lymp J, Li D, Satomura S, Lindor K. Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with nonalcoholic fatty liver disease. Liver Int 2005, 25:779-786. 10.1111/j.1478-3231.2005.01064.x, 15998429.
17. Kaneda H, Hashimoto E, Yatsuji S, Tokushige K, Shiratori K. Hyaluronic acid levels can predict severe fibrosis and platelet counts can predict cirrhosis in patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol 2006, 21:1459-1465.
18. Yoneda M, Mawatari H, Fujita K, Yonemitsu K, Kato S, Takahashi H, Kirikoshi H, Inamori M, Nozaki Y, Abe Y, Kubota K, Saito S, Iwasaki T, Terauchi Y, Togo S, Maeyama S, Nakajima A. Type IV collagen 7s domain is an independent clinical marker of the severity of fibrosis in patients with nonalcoholic steatohepatitis before the cirrhotic stage. J Gastroenterol 2007, 42:375-381. 10.1007/s00535-007-2014-3, 17530362.
19. Harrison SA, Oliver D, Arnold HL, Gogia S, Neuschwander-Tetri BA. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 2008, 57:1441-1447. 10.1136/gut.2007.146019, 18390575.
20. Miyaaki H, Ichikawa T, Nakao K, Yatsuhashi H, Furukawa R, Ohba K, Omagari K, Kusumoto Y, Yanagi K, Inoue O, Kinoshita N, Ishibashi H, Yano M, Eguchi K. Clinicopathological study of nonalcoholic fatty liver disease in Japan: the risk factors for fibrosis. Liver Int 2008, 28:519-524.
21. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, Enders F, Saksena S, Burt AD, Bida JP, Lindor K, Sanderson SO, Lenzi M, Adams LA, Kench J, Therneau TM, Day CP. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007, 45:846-854. 10.1002/hep.21496, 17393509.
22. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, S Sulkowski M, Torriani FJ, Dieterich DT, Thomas DL, Messinger D, Nelson M, . APRICOT Clinical Investigators Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006, 43:1317-1325. 10.1002/hep.21178, 16729309, APRICOT Clinical Investigators.
23. Vallet-Pichard A, Mallet V, Verkarre V, Nalpas A, Dhalluin-Venier V, Fontaine H, Pol S. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology 2007, 46:32-36. 10.1002/hep.21669, 17567829.
24. Shah A, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ, . NASH Clinical Research Network Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009, 7:1104-1112. 10.1016/j.cgh.2009.05.033, 3079239, 19523535, NASH Clinical Research Network.
25. Sumida Y, Yoneda M, Hyogo H, Yamaguchi K, Ono M, Fujii H, Eguchi Y, Suzuki Y, Imai S, Kanemasa K, Fujita K, Chayama K, Yasui K, Saibara T, Kawada N, Fujimoto K, Kohgo Y, Okanoue T, . Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD) A simple clinical scoring system using ferritin, fasting insulin and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease. J Gastroenterol 2011, 46:257-268. 10.1007/s00535-010-0305-6, 20842510, Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD).
26. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ, . Nonalcoholic Steatohepatitis Clinical Research Network Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005, 41:1313-1321. 10.1002/hep.20701, 15915461, Nonalcoholic Steatohepatitis Clinical Research Network.
27. Rickham PP. Human Experimentation. Code of ethics of the world medical association. Declaration of Helsinki. Br Med J 1964, 2:177. 1816102, 14150898.
28. Japanese Society for the Study of Obesity New criteria of obesity (in Japanese). J Jpn Soc Study Obes 2000, 6:18-28. Japanese Society for the Study of Obesity.
29. American Diabetes Association Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997, 20:1183-1197. American Diabetes Association.
30. . Expert Panel on Detection, Treatment of High Blood Cholesterol in Adults Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497. 10.1001/jama.285.19.2486, 11368702, Expert Panel on Detection, Treatment of High Blood Cholesterol in Adults.
31. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, Lok AS. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003, 38:518-526.
32. Poynard T, Bedossa P. Age and platelet count: a simple index for predicting the presence of histological lesions in patients with antibodies to hepatitis C virus. METAVIR and CLINIVIR Cooperative Study Groups. J Viral Hepat 1997, 4:199-208. 10.1046/j.1365-2893.1997.00141.x, 9181529.
33. Fujii H, Enomoto M, Fukushima W, Tamori A, Sakaguchi H, Kawada N. Applicability of BARD score to Japanese patients with NAFLD. Gut 2009, 58:1566-1567. 10.1136/gut.2009.182758, 19834122.
34. Wong VW, Wong GL, Chim AM, Tse AM, Tsang SW, Hui AY, Choi PC, Chan AW, So WY, Chan FK, Sung JJ, Chan HL. Validation of the NAFLD fibrosis score in a Chinese population with low prevalence of advanced fibrosis. Am J Gastroenterol 2008, 103:1682-1688.
35. Fracanzani AL, Valenti L, Bugianesi E, Andreoletti M, Colli A, Vanni E, Bertelli C, Fatta E, Bignamini D, Marchesini G, Fargion S. Risk of Severe Liver Disease in Nonalcoholic Fatty Liver Disease with Normal Aminotransferase Levels: A Role for Insulin Resistance and Diabetes. Hepatology 2008, 48:792-798.
36. Mofrad P, Contos MJ, Haque M, Sargeant C, Fisher RA, Luketic VA, Sterling RK, Shiffman ML, Stravitz RT, Sanyal AJ. Clinical and Histologic Spectrum of Nonalcoholic Fatty Liver Disease Associated With Normal ALT Values. Hepatology 2003, 37:1286-1292. 10.1053/jhep.2003.50229, 12774006.
37. Uslusoy HS, Nak SG, Gülten M, Biyikli Z. Non-alcoholic steatohepatitis with normal aminotransferase values. World J Gastroenterol 2009, 21:1863-1868.